Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMA-VACC study of SARS-CoV-2 vaccine response in secondary progressive multiple sclerosis patients treated with siponimod
2020-005752-38Phase 4Completed
- Sponsor
- Novartis
- Start
- Jan 2021
- Modality
- Small Molecules, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of siponimod and RH109 in secondary-progressive multiple sclerosis (SPMS) and coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Novartis. Primary endpoint: Primary: Seroconversion after second vaccine dose. Started Jan 2021; status: completed.
02
Drugs
siponimodRH109
03
Conditions
secondary-progressive multiple sclerosis (SPMS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005752-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005752-38.